A pharmaceutical company has developed a new antimicrobial

that is active against multidrug-resistant organisms. In clinical practice,

these infections are typically treated with existing agents that are effective

but associated with significant toxicity or resistance concerns. When seeking

regulatory approval, the company designs its pivotal trials as non-inferiority

studies rather than superiority trials.

Which rationale best explains this choice?